[ Inside the business ]

ENVB stock analysis

ENVB · Enveric Biosciences, Inc.

Pharmaceutical preparations. Shrinking 7%.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#7 of 20 mentioning it
03 Will customers keep buying?Sales −7%, steady
No customer over 10%
Sales −7%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
Before running costs: 19% → 20%
06 Can it fund itself?0.0 yrs of cash
05 yrs10+ yrs
Shares +698.7%/yrDebt $0
07 What could break it?2 to watch
  • Going-concern warning
  • Heavy dilution

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth −10%, −25%, then −7% vs. a year ago.

What could go wrong

Red flags.

It has moved 1.2× the market. In the 2022 rate shock it fell 91% while the market fell 24%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Speculative.

Speculative: going-concern warning; operating loss, cash flowing out of operations, under $1B in sales. Cash runway: 0.0 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Introduction.

It uses cash, invests, and raises money to keep going.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

2 of 5 years.

Returns beat its 10.0% cost of capital in 2 of the last 5 years. Gross margin went from 15% to 20%.

Future bets

0% on equipment.

$0M a year on equipment and buildings.

All figures from Enveric Biosciences, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.